Loading…
Biomarker implementation: Evaluation of the decision‐making impact of CXCL10 testing in a pediatric cohort
Background Children are at high risk for subclinical rejection, and kidney biopsy is currently used for surveillance. Our objective was to test how novel rejection biomarkers such as urinary CXCL10 may influence clinical decision‐making to indicate need for a biopsy. Methods A minimum dataset for st...
Saved in:
Published in: | Pediatric transplantation 2021-05, Vol.25 (3), p.e13908-n/a |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Children are at high risk for subclinical rejection, and kidney biopsy is currently used for surveillance. Our objective was to test how novel rejection biomarkers such as urinary CXCL10 may influence clinical decision‐making to indicate need for a biopsy.
Methods
A minimum dataset for standard decision‐making to indicate a biopsy was established by an expert panel and used to design clinical vignettes for use in a survey. Pediatric nephrologists were recruited to review the vignettes and A) estimate rejection risk and B) decide whether to biopsy; first without and then with urinary CXCL10/Cr level. Accuracy of biopsy decisions was then tested against the biopsy results. IRA was assessed by Fleiss Kappa (κ) for binary choice and ICC for probabilities.
Results
Eleven pediatric nephrologists reviewed 15 vignettes each. ICC of probability assessment for rejection improved from poor (0.28, P |
---|---|
ISSN: | 1397-3142 1399-3046 |
DOI: | 10.1111/petr.13908 |